The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic
heterogeneity. Several risk factors including advanced age, previous illnesses, and a …

Background Hematopoietic stem cell transplant (HSCT) recipients are at increased risk of
mortality and morbidity with coronavirus disease 2019 (COVID‐19) due to severe immune …

Background: During the first wave of COVID-19, hydroxychloroquine (HCQ) was used off-
label despite the absence of evidence documenting its clinical benefits. Since then, a meta …

Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …

Key Points The EHA-IDWP developed an observational registry collecting data on COVID-
19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was …

Background The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation
(HSCT) recipients is almost uniformely considered poor. The aim of present study was to …

Hematopoietic stem cell transplants (HSCT) are becoming more widespread as a result of
optimization of conditioning regimens and prevention of short-term complications with …

HSCT recipients are at increased risk for COVID-19-associated morbidity and mortality.
Early treatment of symptomatic SARS-CoV-2 infection is an important means to decreasing …

Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) recipients are especially
vulnerable to coronavirus disease 19 (COVID-19), because of their profound …

Background One year into the pandemic, published data on hematopoietic cell
transplantation (HCT) recipients with coronavirus disease 2019 (COVID‐19) remain limited …